54 related articles for article (PubMed ID: 8632421)
1. Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption.
von Geldern TW; Hoffman DJ; Kester JA; Nellans HN; Dayton BD; Calzadilla SV; Marsh KC; Hernandez L; Chiou W; Dixon DB; Wu-Wong JR; Opgenorth TJ
J Med Chem; 1996 Feb; 39(4):982-91. PubMed ID: 8632421
[TBL] [Abstract][Full Text] [Related]
2. Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile.
von Geldern TW; Hutchins C; Kester JA; Wu-Wong JR; Chiou W; Dixon DB; Opgenorth TJ
J Med Chem; 1996 Feb; 39(4):957-67. PubMed ID: 8632419
[TBL] [Abstract][Full Text] [Related]
3. Azole endothelin antagonists. 2. Structure-activity studies.
von Geldern TW; Kester JA; Bal R; Wu-Wong JR; Chiou W; Dixon DB; Opgenorth TJ
J Med Chem; 1996 Feb; 39(4):968-81. PubMed ID: 8632420
[TBL] [Abstract][Full Text] [Related]
4. Absorption, distribution, metabolism, and excretion considerations in selection of orally active indole-containing endothelin antagonist.
Walker DK; Dack KN; Dickinson RP; Fenner KS; James K; Rawson DJ; Smith DA
Drug Metab Dispos; 2001 Nov; 29(11):1424-31. PubMed ID: 11602517
[TBL] [Abstract][Full Text] [Related]
5. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
[TBL] [Abstract][Full Text] [Related]
6. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
Jae HS; Winn M; Dixon DB; Marsh KC; Nguyen B; Opgenorth TJ; von Geldern TW
J Med Chem; 1997 Sep; 40(20):3217-27. PubMed ID: 9379441
[TBL] [Abstract][Full Text] [Related]
7. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
[TBL] [Abstract][Full Text] [Related]
8. Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists.
Betts A; Atkinson F; Gardner I; Fox D; Webster R; Beaumont K; Morgan P
Drug Metab Dispos; 2007 Aug; 35(8):1435-45. PubMed ID: 17502340
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of endothelin A and B receptor antagonism on fetal growth in normal and nitric oxide-deficient rats.
Thaete LG; Neerhof MG; Silver RK
J Soc Gynecol Investig; 2001; 8(1):18-23. PubMed ID: 11223352
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists.
Riechers H; Albrecht HP; Amberg W; Baumann E; Bernard H; Böhm HJ; Klinge D; Kling A; Müller S; Raschack M; Unger L; Walker N; Wernet W
J Med Chem; 1996 May; 39(11):2123-8. PubMed ID: 8667356
[TBL] [Abstract][Full Text] [Related]
12. Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
Wu C; Decker ER; Blok N; Bui H; You TJ; Wang J; Bourgoyne AR; Knowles V; Berens KL; Holland GW; Brock TA; Dixon RA
J Med Chem; 2004 Apr; 47(8):1969-86. PubMed ID: 15055997
[TBL] [Abstract][Full Text] [Related]
13. Estimation of blood levels of endothelin and neurokinin receptor antagonists at the rat portal and jugular veins after oral administration as a tool in peptide drug design.
Paladino J; Kucharczyk N; Morris AD; Thibault-Naze M; Mahieu JP; Serkiz B; Volland JP; Autissier C; Fauchere JL
Drug Des Discov; 1994 Nov; 12(2):121-8. PubMed ID: 9116167
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
[TBL] [Abstract][Full Text] [Related]
15. 2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
Winn M; von Geldern TW; Opgenorth TJ; Jae HS; Tasker AS; Boyd SA; Kester JA; Mantei RA; Bal R; Sorensen BK; Wu-Wong JR; Chiou WJ; Dixon DB; Novosad EI; Hernandez L; Marsh KC
J Med Chem; 1996 Mar; 39(5):1039-48. PubMed ID: 8676339
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.
Liu G; Kozmina NS; Winn M; von Geldern TW; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 1999 Sep; 42(18):3679-89. PubMed ID: 10479299
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of a novel class of endothelin receptor selective antagonists; 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridines.
Takahashi H; Ohtake N; Sakamoto T; Iino T; Kawanishi N; Nakamura M; Yoshizumi T; Niiyama K; Ozaki S; Okada H; Kano A; Takahashi H; Ishii Y; Okada M; Saito M; Sawazaki Y; Hayama T; Nishikibe M
Bioorg Med Chem Lett; 2004 Mar; 14(6):1503-7. PubMed ID: 15006391
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of N2-aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists.
Wu C; Chan MF; Stavros F; Raju B; Okun I; Castillo RS
J Med Chem; 1997 May; 40(11):1682-9. PubMed ID: 9171877
[TBL] [Abstract][Full Text] [Related]
20. Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy.
Wolf SC; Amend T; Risler T; Amann K; Brehm BR
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():276S-279S. PubMed ID: 12193103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
